Altimmune, Inc. (ALT)

Altimmune's stock price has experienced volatility and a general decline over the past six months. In November 2025, Altimmune participated in investor conferences. In December 2025, the company announced positive 48-week topline results from the IMPACT Phase 2b trial of pemvidutide in MASH patients and a CEO transition. In January 2026, Pemvidutide received FDA Breakthrough Therapy Designation for MASH, but the closing of a $75 million registered direct offering of common stock led to a stock price decline. In March 2026, Altimmune reported its fourth quarter and full-year 2025 financial results, detailing a net loss but also a strengthened cash position. The stock received a rating downgrade from some analysts due to concerns about funding needs and increasing competitive headwinds.

As a clinical-stage biopharmaceutical company, Altimmune does not currently have commercialized products or services with established market demand seasonality. The company's financial performance and stock price are more influenced by clinical trial milestones, regulatory approvals, financing activities, and broader biotechnology market trends rather than seasonal consumer demand.

Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing therapies for liver and metabolic diseases. Their lead product, pemvidutide, is in development for MASH, AUD, ALD, and obesity. The company also has HepTcell in Phase 2 development for chronic hepatitis B. Altimmune was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune, Inc. is based in Gaithersburg, Maryland, where it conducts its corporate activities and oversees its clinical programs. The company's stock is listed on several international exchanges, indicating a global presence for its trading activities. Altimmune plans to initiate a global Phase 3 registrational trial for pemvidutide in MASH, suggesting an international scope for its clinical development operations. The company also has wholly-owned subsidiaries including Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Altimmune's brand reputation has been shaped by positive scientific advancements and financial concerns. Positive clinical trial results and regulatory designations have reinforced its scientific credibility. However, analyst downgrades, funding concerns, and intensifying competition in the MASH treatment landscape have posed challenges to the company's reputation.

Altimmune, Inc. has a diverse ownership structure, with significant holdings by institutional, individual, and retail investors. Institutional investors hold approximately 26.41% to 42.17% of the company's stock, with major shareholders including BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Individual investors hold a substantial portion of shares, ranging from 59% to 72.95%. Insiders hold approximately 0.65% to 48.78% of the company's stock, with Prescott Group Capital Management LLC being the largest individual shareholder.